Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527–540 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 (2025).

PubMed  PubMed Central  Google Scholar 

Wang, J. et al. Consensus, debate, and prospective on pancreatic cancer treatments. J. Hematol. Oncol. 17, 92 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Finan, J. M., Guo, Y., Goodyear, S. M. & Brody, J. R. Challenges and opportunities in targeting the complex pancreatic tumor microenvironment. JCO Oncol. Adv. 18, e2400050 (2024).

Article  Google Scholar 

Ju, Y. et al. Barriers and opportunities in pancreatic cancer immunotherapy. npj Precis. Oncol. 8, 199 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3, 272–286 (2022).

Article  PubMed  Google Scholar 

Haldar, S. D. & Azad, N. S. Unlocking the promise of RAS inhibition in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 535–536 (2024).

Article  CAS  PubMed  Google Scholar 

Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487–505 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Bachem, M. G. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907–921 (2005).

Article  CAS  PubMed  Google Scholar 

Li, K. Y. et al. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chronic Dis. Transl. Med. 6, 6–17 (2020).

PubMed  PubMed Central  Google Scholar 

Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tjomsland, V. et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin. Dev. Immunol. 2011, 212810 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Perez, V. M., Kearney, J. F. & Yeh, J. J. The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies. Front. Oncol. 11, 751311 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, D. et al. The extracellular matrix: a key accomplice of cancer stem cell migration, metastasis formation, and drug resistance in PDAC. Cancers 14, 3998 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whatcott, C. J. et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 21, 3561–3568 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laklai, H. et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22, 497–505 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian, C. et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc. Natl Acad. Sci. USA 116, 19609–19618 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian, C. et al. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nat. Commun. 12, 2328 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, Y. et al. Type I collagen deletion in —SMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39, 548–565.e6 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhattacharjee, S. et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J. Clin. Invest. 131, e146987 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 40, 818–834.e9 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steele, N. G. et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer. Clin. Cancer Res. 27, 2023–2037 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Jesus-Acosta, A. et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br. J. Cancer 122, 498–505 (2020).

Article  PubMed  Google Scholar 

Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185–3194 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kemper, M. et al. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. J. Exp. Clin. Cancer Res. 40, 214 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomas Bort, E. et al. Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. eLife 12, e86971 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Reader, C. S. et al. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J. Pathol. 249, 332–342 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar